Tuesday, 20 Mar 2018

You are here

Increasing Adverse Events Seen with Higher Disease Activity in Early RA

Researchers in the NEO-RACo Study Group studied adverse events (AEs) in relation to disease activity in patients with early rheumatoid arthritis (RA).

They followed 99 ERA  patients who started intensive treatment with three conventional synthetic DMARDs (csDMARDs) and oral prednisolone, and were randomized to a 6-month induction treatment with infliximab or placebo. AEs were scored and related to disease activity, including the 28-joint disease activity score (DAS28) and remission rates at 12 and 24 months.

These patients averaged 5.4 ± 4.3 AEs (total 331) and 8% (27) experienced severe or serious AE.

24% of AE lead to drug discontinuation that was temporary (n = 52) or permanent (n = 27) .

Far more discontinuations and AEs were seen with increasing tertiles of DAS28 activity.

An overall higher burden of AEs is associated with higher disease activity and lower likelihood of remission in early RA.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Using Synovial Tissue Biopsies to Develop Precision Medicine for Rheumatoid Arthritis

Researchers at Northwestern University have used ultrasound-guided tissue biopsy from the joints to analyze the genes of tissue macrophages with the hope that transcriptional profiling of synovial macrophages may be correlated with clinical parameters or drug responsiveness in rheumatoid arthritis (RA) patients.(Citation source: 

IL-18 Binding Protein Effective in Adult-Onset Still's Disease

Gabay and colleagues have reported the results of a novel new recombinant human IL-18 binding protein, tadekinig alfa, demonstrating its effectiveness in an open-label dose escalating study in patients with adult-onset Still's disease (AOSD).

NHANES Survey Shows OA Rising and RA Declining

An analysis of 43,706 adults from the 1999-2014 National Health and Nutrition Examination Surveys (NHANES) demonstrated temporal trends in the prevalence of arthritis, including a rise in osteoarthritis (OA) from 6.6% to 14.3%, while the prevalence of rheumatoid arthritis (RA) decreased from 5.9% to 3.8% in the USA, (Citation source https://buff.ly/2o6fhkW

DMARDs Lower Dementia Risk in Rheumatoid Arthritis

UK researchers have analyzed rheumatoid arthritis (RA) patients from the UK Clinical Practice Research Database and shown that chronic conventional DMARD (cDMARD) use was associated with 40% lower risk of dementia (nearly 50% with methotrexate use).

Abatacept Shows Promise for RA-ILD

Abatacept (Orencia) may be a useful treatment option for patients with rheumatoid arthritis (RA) who develop interstitial lung disease (ILD), a Spanish study suggested.